<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff" style='font-family:"Times New Roman"'>




<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><B><font SIZE=4>UNITED STATES</font></B></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><B><font SIZE=4>SECURITIES AND EXCHANGE COMMISSION</font></B></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><B><font SIZE=2>WASHINGTON, D.C. 20549</font></B></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><font size=2>____________________</font></p>

<p style=' margin-bottom:12pt; margin-top:12pt;text-align:center;'><B><font SIZE=5>FORM 8-K</font></B></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><B><font SIZE=2>CURRENT REPORT</font></B></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Pursuant to Section 13 or 15(d) of the </font></b></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><b><font size=2>Securities Exchange Act of 1934</font></b></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><font size=2>Date of report (Date of earliest event reported):  </font><b><font size=2>May 21, 2009</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=4>Emergent BioSolutions Inc.</font></b></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><font size=2>(Exact Name of Registrant as Specified in Charter)</font></p>


<div align=center>

<table border="0" cellspacing=0 cellpadding=0 width="638" style='border-collapse:collapse'>
    <tr >
        <td width="223" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:3.0pt;text-align:center'><b><font size=2>Delaware</font></b></p> </td>
        <td width="192" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:3.0pt;text-align:center'><b><font size=2>001-33137</font></b></p> </td>
        <td width="223" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:3.0pt;text-align:center'><b><font size=2>14-1902018</font></b></p> </td> </tr>
    <tr >
        <td width="223" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:0in;text-align:center'><font size=2>(State or Other Jurisdiction</font></p>
<p  align=center style='margin-bottom:0in;text-align:center'><font size=2>of Incorporation)</font></p> </td>
        <td width="192" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:0in;text-align:center'><font size=2>(Commission</font><br> <font size=2>File Number)</font></p> </td>
        <td width="223" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:0in;text-align:center'><font size=2>(IRS Employer</font><br> <font size=2>Identification No.)</font></p> </td> </tr></table>
</div>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>


<div align=center>

<table border="0" cellspacing=0 cellpadding=0 width="638" style='border-collapse:collapse'>
    <tr >
        <td width="415" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:3.0pt;text-align:center'><b><font size=2>2273 Research Boulevard, Suite 400, Rockville, Maryland</font></b></p> </td>
        <td width="223" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-bottom:3.0pt;text-align:center'><b><font size=2>20850</font></b></p> </td> </tr>
    <tr >
        <td width="415" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-top:3.0pt;margin-right:0in; margin-bottom:0in;margin-left:0in;text-align:center'><font size=2>(Address of Principal Executive Offices)</font></p> </td>
        <td width="223" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  align=center style='margin-top:3.0pt;margin-right:0in; margin-bottom:0in;margin-left:0in;text-align:center'><font size=2>(Zip Code)</font></p> </td> </tr></table>
</div>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><font size=2>Registrant&#146;s telephone number, including area code:  </font><b><font size=2>(301) 795-1800</font></b></p>

<p style=' margin-bottom:3pt; margin-top:0pt;text-align:center;'><b><font size=2>Not applicable</font></b></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><font size=2>(Former Name or Former Address, if Changed Since Last Report)</font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face=Wingdings>o</font><font size=2> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face=Wingdings>o</font><font size=2> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face=Wingdings>o</font><font size=2> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face=Wingdings>o</font><font size=2> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<div TITLE="EE+ Page Footer">
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font SIZE=2></font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2> </font></p>
</DIV>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<div TITLE="EE+ Page Break" STYLE="PAGE-BREAK-AFTER: always">

<HR noshade align="center" width="100%" size="2">
</DIV>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><b><font face="Arial" size=2>Item 5.02</font></b><font face="Arial" size=2>&nbsp;</font><b><font face="Arial" size=2> Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>On May 21, 2009, the stockholders of Emergent BioSolutions Inc. approved the Emergent BioSolutions Inc. Amended and Restated 2006 Stock Incentive Plan (the &#147;Amended Plan&#148;), triggering the effectiveness of the Amended Plan. The board of directors adopted the Amended Plan on March 31, 2009, subject to stockholder approval.&nbsp; Among other things, the Amended Plan:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face="Arial" size=2>&#149; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases the number of shares of our common stock available for issuance under the 2006 Stock Incentive Plan by 3,900,000 shares, subject to adjustment in the event of stock splits and other similar events;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face="Arial" size=2>&#149; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; implements a &#147;fungible share pool,&#148; which is a method of computing the maximum aggregate number of shares of common stock available for issuance under the Amended Plan by assigning weighted values to different types of awards under the Amended Plan without assigning specific limits for various awards</font><font color="#000080"><font face="Arial" size=2>;</font></font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face="Arial" size=2>&#149; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; establishes that the aggregate number of shares of common stock with respect to which a stock-settled stock appreciation right is exercised, rather than the number of shares of common stock actually issued upon exercise, will be counted against the number of shares of common stock available for awards under the Amended Plan;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face="Arial" size=2>&#149; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; establishes a maximum term and a minimum base amount for a stock appreciation right not expressly granted in tandem with a stock option;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face="Arial" size=2>&#149; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clarifies that the board of directors may not take any action that is expressly prohibited by the repricing provisions of the Amended Plan;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font face="Arial" size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face="Arial" size=2>&#149; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; extends the term of the Amended Plan until December 31, 2019; and</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>
<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font face="Arial" size=2>&#149; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clarifies that stockholder approval is required for any amendment to the Amended Plan that would materially increase the number of shares of common stock available for issuance under the Amended Plan (other than an increase to reflect permitted adjustments) or would materially expand the class of service providers eligible to participate in the Amended Plan.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>

<div TITLE="EE+ Page Footer">
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font SIZE=2></font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2> </font></p>
</DIV>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<div TITLE="EE+ Page Break" STYLE="PAGE-BREAK-AFTER: always">

<HR noshade align="center" width="100%" size="2">
</DIV>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>
</p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:center;'><B><font SIZE=2>SIGNATURE</font></B></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:left;'><font size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>


<div align=left>

<table border="0" cellspacing=0 cellpadding=0 width="638" style='border-collapse:collapse'>
    <tr >
        <td width="319" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  style='margin-bottom:.25in'><font size=2>Date:  May 28, 2009</font></p> </td>
        <td  colspan="2" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p  style='margin-bottom:.25in'><font SIZE=2>EMERGENT BIOSOLUTIONS INC.</font></p> </td> </tr>
    <tr style='page-break-inside:avoid; height:62.25pt'>
        <td width="319" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:62.25pt'>
            <p  align=right style='text-align:right'><font size=1>&nbsp;</font></p> </td>
        <td width="36" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:62.25pt'>
            <p  align=right style='text-align:right'><font size=2>By:</font></p> </td>
        <td width="283" valign=top style='padding:0in 5.4pt 0in 5.4pt; height:62.25pt'>
            <p  style='margin-bottom:0in'><u><font size=2>/s/ Denise Esposito</font></u></p>
<p  style='margin-bottom:0in'><font size=2>Denise Esposito</font></p>
<p  style='margin-bottom:0in'><font size=2>Chief Legal Officer</font></p>
<p  style='margin-bottom:0in'><font size=2>SVP, Legal Affairs </font></p> </td> </tr></table>
</div>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<div TITLE="EE+ Page Footer">
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font SIZE=2></font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2> </font></p>
</DIV>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>



</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "form8-k.htm", "secsgml_size_bytes": 14151}]
{"company-data": {"conformed-name": "Emergent BioSolutions Inc.", "cik": "0001367644", "assigned-sic": "2834", "irs-number": "141902018", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33137", "film-number": "09857230"}, "business-address": {"street1": "2273 RESEARCH BLVD, SUITE 400", "city": "ROCKVILLE", "state": "MD", "zip": "20850", "phone": "(301) 795-1800"}, "mail-address": {"street1": "2273 RESEARCH BLVD, SUITE 400", "city": "ROCKVILLE", "state": "MD", "zip": "20850"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 21, 2009
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-33137
14-1902018
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2273 Research Boulevard, Suite 400, Rockville, Maryland
20850
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(301) 795-1800
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 21, 2009, the stockholders of Emergent BioSolutions Inc. approved the Emergent BioSolutions Inc. Amended and Restated 2006 Stock Incentive Plan (the "Amended Plan"), triggering the effectiveness of the Amended Plan. The board of directors adopted the Amended Plan on March 31, 2009, subject to stockholder approval.  Among other things, the Amended Plan:
•        increases the number of shares of our common stock available for issuance under the 2006 Stock Incentive Plan by 3,900,000 shares, subject to adjustment in the event of stock splits and other similar events;
•        implements a "fungible share pool," which is a method of computing the maximum aggregate number of shares of common stock available for issuance under the Amended Plan by assigning weighted values to different types of awards under the Amended Plan without assigning specific limits for various awards
;
•        establishes that the aggregate number of shares of common stock with respect to which a stock-settled stock appreciation right is exercised, rather than the number of shares of common stock actually issued upon exercise, will be counted against the number of shares of common stock available for awards under the Amended Plan;
•        establishes a maximum term and a minimum base amount for a stock appreciation right not expressly granted in tandem with a stock option;
•        clarifies that the board of directors may not take any action that is expressly prohibited by the repricing provisions of the Amended Plan;
•        extends the term of the Amended Plan until December 31, 2019; and
•        clarifies that stockholder approval is required for any amendment to the Amended Plan that would materially increase the number of shares of common stock available for issuance under the Amended Plan (other than an increase to reflect permitted adjustments) or would materially expand the class of service providers eligible to participate in the Amended Plan.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:  May 28, 2009
EMERGENT BIOSOLUTIONS INC.
By:
/s/ Denise Esposito
Denise Esposito
Chief Legal Officer
SVP, Legal Affairs